Legal Representation
Attorney
Douglas R. Wolf
USPTO Deadlines
Next Deadline
547 days remaining
Section 8 Declaration Due (Principal Register) (Based on registration date 20210622)
Due Date
June 22, 2027
Grace Period Ends
December 22, 2027
Additional deadlines exist. Contact your attorney for complete deadline information.
Application History
28 events| Date | Code | Type | Description | Documents |
|---|---|---|---|---|
| Mar 19, 2025 | ASCK | I | ASSIGNMENT OF OWNERSHIP NOT UPDATED AUTOMATICALLY | Loading... |
| Mar 5, 2025 | ASGN | I | AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP | Loading... |
| Jul 16, 2024 | TCCA | I | TEAS CHANGE OF CORRESPONDENCE RECEIVED | Loading... |
| Jul 16, 2024 | ARAA | I | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED | Loading... |
| Jul 16, 2024 | REAP | I | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED | Loading... |
| Jul 16, 2024 | CHAN | I | APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED | Loading... |
| Jul 16, 2024 | COAR | I | TEAS CHANGE OF OWNER ADDRESS RECEIVED | Loading... |
| Jun 22, 2021 | R.PR | A | REGISTERED-PRINCIPAL REGISTER | Loading... |
| Apr 6, 2021 | NPUB | E | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | Loading... |
| Apr 6, 2021 | PUBO | A | PUBLISHED FOR OPPOSITION | Loading... |
| Mar 17, 2021 | NONP | E | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | Loading... |
| Mar 1, 2021 | CNSA | O | APPROVED FOR PUB - PRINCIPAL REGISTER | Loading... |
| Feb 8, 2021 | TEME | I | TEAS/EMAIL CORRESPONDENCE ENTERED | Loading... |
| Feb 8, 2021 | CRFA | I | CORRESPONDENCE RECEIVED IN LAW OFFICE | Loading... |
| Feb 8, 2021 | ERFR | I | TEAS REQUEST FOR RECONSIDERATION RECEIVED | Loading... |
| Sep 9, 2020 | GNFN | O | NOTIFICATION OF FINAL REFUSAL EMAILED | Loading... |
| Sep 9, 2020 | GNFR | O | FINAL REFUSAL E-MAILED | Loading... |
| Sep 9, 2020 | CNFR | R | FINAL REFUSAL WRITTEN | Loading... |
| Aug 18, 2020 | TEME | I | TEAS/EMAIL CORRESPONDENCE ENTERED | Loading... |
| Aug 18, 2020 | CRFA | I | CORRESPONDENCE RECEIVED IN LAW OFFICE | Loading... |
| Aug 18, 2020 | TROA | I | TEAS RESPONSE TO OFFICE ACTION RECEIVED | Loading... |
| Feb 21, 2020 | GNRN | O | NOTIFICATION OF NON-FINAL ACTION E-MAILED | Loading... |
| Feb 21, 2020 | GNRT | F | NON-FINAL ACTION E-MAILED | Loading... |
| Feb 21, 2020 | CNRT | R | NON-FINAL ACTION WRITTEN | Loading... |
| Feb 20, 2020 | DOCK | D | ASSIGNED TO EXAMINER | Loading... |
| Nov 22, 2019 | MDSC | E | NOTICE OF DESIGN SEARCH CODE E-MAILED | Loading... |
| Nov 21, 2019 | NWOS | I | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | Loading... |
| Nov 19, 2019 | NWAP | I | NEW APPLICATION ENTERED | Loading... |
Detailed Classifications
Class 005
pharmaceutical drugs, preparations and medications for use in the prevention, reduction and treatment of cardiovascular disorders, allergies, anaphylaxis, central nervous system disorders, peripheral nervous system disorders, reproductive health disorders, electrolytic imbalance, caloric imbalance, obesity, nutritional disorders, autoimmune disorders, endocrine disorders, gastrointestinal disorders, inflammatory disorders, dermatological disorders, infectious diseases, hormonal imbalance, pain, complications arising from organ transplantation, cancer, pulmonary disorders, renal disorders, urinary system disorders, ophthalmic disorders, otic disorders, sense organ disorders, dental disorders, musculoskeletal disorders, diabetic disorders, neuromuscular disorders, bone disorders, blood disorders, metabolic disorders, psychosis; pharmaceutical drugs, preparations and medications for use in sedation, analgesia, anaesthesia; pharmaceutical drugs, preparations and medications for use in the prevention, reduction and treatment of senile disorders, sleep disorders, dementia, congenital disease disorders, abnormal gene disorders, hair growth disorders, gynaecological diseases, obstetric disorders, withdrawal syndromes, hormonal disorders, urogenital organ disorders, sexual dysfunction, nausea and vomiting, emesis, migraine, edema, multiple sclerosis, chronic obstructive pulmonary disorder, depression, pregnancy, spasms, hypertension, hypotension, angioedema, fungal diseases, fertility disorders, hyperglycemia, hypoglycemia, post-operative disorders, arthritis, psoriasis and localized fat deposits; pharmaceutical and biological preparations for use in diagnosis, namely, for use as and X-ray contrast reagents
First Use Anywhere:
20170000
First Use in Commerce:
20181200
Additional Information
Design Mark
The mark consists of a stylized design of a molecule with eight large circles and four small circles connected with straight lines and eight small circles positioned around it.
Color Claim
Color is not claimed as a feature of the mark.
Classification
International Classes
005